Cancer researchHumansCarcinomaNon-Small-Cell LungDrug ResistanceNeoplasm
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.
Hitendra S Solanki, Harshit Shah, Denis Imbody, Bina Desai, Ryoji Kato, Daria Miroshnychenko, Yaakov E Stern, Anurima Majumder, Bhaswati Sarcar, Aobuli Xieraili, Paul A Stewart, Bin Fang, Yonghong Zhang, Jiqiang Yao, Lancia N Darville
Published: 202610.1158/0008-5472.CAN-25-0600
Abstract
Small-molecule KRASG12C(OFF) inhibitors that bind to the inactive GDP-bound state of KRAS have demonstrated efficacy in patients with KRASG12C-mutant tumors, yet responses tend to be transient because of emergence of on-treatment resistance. Recently…
Preview only. Read the full abstract at the source